Teleflex to Present at Annual Meeting of the Association for Vascular Access (AVA)
September 08 2014 - 9:00AM
Business Wire
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical devices for critical care and surgery, announces that its
technology will be the subject of symposiums and scientific
presentations at the upcoming annual meeting of the Association for
Vascular Access (AVA). Teleflex will also host AVA’s first-ever
vascular access cadaver lab at the conference.
AVA 2014 will be held September 7-10 at the Gaylord National
Resort and Convention Center, in National Harbor, MD.
The cadaver lab and several of the Teleflex symposiums and
poster presentations include products from the ARROW® Brand
portfolio. The portfolio includes vascular access devices such as
antimicrobial and antithrombogenic PICCs and CVCs; the ARROW® VPS
G4™ Vascular Positioning System®; and the new ARROW® EZ-IO® Needle
+ Stabilizer Kit. These products assist healthcare facilities in
striving to achieve a goal of zero complications in vascular care
by providing protection against catheter infection, thrombosis,
occlusion, and malposition.
Teleflex will be at Booth 221 in Prince George’s Exhibition Hall
E during the conference. At its booth, the company will focus
special attention on its Chlorag+ard® Technology. This includes the
ARROW® JACC with Chlorag+ard® Technology, the world’s only
antimicrobial and antithrombogenic CVC, and the ARROW® PICC with
Chlorag+ard® Technology, the world’s only antimicrobial and
antithrombogenic PICC.
The cadaver lab will provide a unique hands-on opportunity for
participants to practice vascular-access techniques as well as
receive an in-depth review of associated anatomy on cadaveric
specimens. It will be held Monday, September 8 from 7-9 p.m. in
Potomac D on the convention center’s second level.
Other presentations include:
- Showcase – “You Can’t Afford Not to
Understand Affordable Care” showcase with speaker Leslie Schultz,
AN, PhD, CPHQ. 3:30 p.m., Monday, September 8, in Potomac 1-2.
- Dinner Symposium – “Chlorag+ard®
Technology: Reducing a Triad of Associated Complications”, Kamna
Giare-Patel, MS, AN, and Rebekah Limato, BS, ART. Monday, September
8, 7 p.m. in Potomac C on the second level.
- Breakfast Symposium – “Preserving
Vascular Real Estate: Location is Important for the Renal Patient.”
The speaker is Peter Wayne, MD. 7 a.m. Tuesday, September 9 in
Potomac C on the second level.
The following are among 9 poster presentations at AVA evaluating
technology from Teleflex:
- “Catheter technologies: Is eluting
technology or non-eluting technology more effective in preventing
thrombus accumulation?” by Kamna Giare-Patel, MS, et al. This study
evaluated the effectiveness of three types of peripherally inserted
central venous catheters (PICCs) as compared to uncoated PICCs, in
a clinically simulated ovine model.
- “Are antibiotic-resistant ‘superbugs’ a
real challenge to antimicrobial central venous catheter
performance?” by Nisha Gupta, PhD, et al. The research compared the
in vitro effectiveness of three antimicrobial CVCs against
gram-positive and gram-negative “superbugs”.
- “Are PICCs with eluting technology more
effective against antibiotic-resistant bacteria than non-eluting
technology?” by Nisha Gupta, PhD, et al. The authors compared the
antimicrobial effectiveness of three different types of PICCs
against six antibiotic-resistant superbugs.
- “Can PICC technologies prevent catheter
colonization by CLABSI-causing pathogens?” by Nisha Gupta, PhD, et
al. Researchers compared the antimicrobial effectiveness of three
different types of PICCs against 12 common pathogens responsible
for causing central line-associated bloodstream infections
(CLABSIs).
The posters will be displayed on Monday, September 8 from 8 a.m.
to 5 p.m.; Tuesday, September 9 from 8 a.m. to 5 p.m.; and
Wednesday, September 10 from 7 to 11:30 a.m. Authors will be
available to answer questions about their posters on Monday, Sept.
8 from 8 to 9 a.m. and Tuesday, September 9 from 8 to 9 a.m.
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical
devices for a range of procedures in critical care and surgery. Our
mission is to provide solutions that enable healthcare providers to
improve outcomes and enhance patient and provider safety.
Headquartered in Wayne, PA, Teleflex employs approximately 11,500
people worldwide and serves healthcare providers in more than 150
countries. Additional information about Teleflex can be obtained
from the company's website at teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management's current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, Arrow, Chlorag+ard, EZ-IO, Vascular Positioning System
and VPS G4 are trademarks or registered trademarks of Teleflex
Incorporated or its affiliates.
© 2014 Teleflex Incorporated. All rights reserved. MC-000536
Teleflex IncorporatedJake Elguicze, 610-948-2836Treasurer and
Vice President, Investor Relations
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024